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Objectives: Emerging evidence supports the use of therapeutic drug monitoring (TDM) of b-lactams for intensive
care unit (ICU) patients to optimize drug exposure, although limited detail is available on how sites run this ser-
vice in practice. This multicentre survey study was performed to describe the various approaches used for
b-lactam TDM in ICUs.
Methods: A questionnaire survey was developed to describe various aspects relating to the conduct of b-lactam
TDM in an ICU setting. Data sought included: b-lactams chosen for TDM, inclusion criteria for selecting patients,
blood sampling strategy, analytical methods, pharmacokinetic (PK)/pharmacodynamic (PD) targets and dose
adjustment strategies.
Results: Nine ICUs were included in this survey. Respondents were either ICU or infectious disease physicians,
pharmacists or clinical pharmacologists. Piperacillin (co-formulated with tazobactam) and meropenem (100%
of units surveyed) were the b-lactams most commonly subject to TDM, followed by ceftazidime (78%), ceftriax-
one (43%) and cefazolin (43%). Different chromatographic and microbiological methods were used for assay of
b-lactam concentrations in blood and other biological fluids (e.g. CSF). Therewas significant variation in the PK/PD
targets (100% fT.MIC up to 100% fT.4×MIC) and dose adjustment strategies used by each of the sites.
Conclusions: Large variations were found in the type of b-lactams tested, the patients selected for TDM and drug
assaymethods. Significant variation observed in the PK/PD targets and dose adjustment strategies used supports
the need for further studies that robustly define PK/PD targets for ICU patients to ensure a greater consistency of
practice for dose adjustment strategies for optimizing b-lactam dosing with TDM.
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Introduction
Therapeutic drug monitoring (TDM) is a commonly utilized dosing
strategy to minimize toxicity and maximize the efficacy of drugs
with a narrow therapeutic index. It is most commonly used when
the pharmacokinetics (PK) and therefore the optimal dose of a
drug for an individual patient are difficult to predict. In clinical
practice, the approach has been routinely used for many years
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for vancomycin and aminoglycosides, selected anticonvulsants,
anticoagulants and antipsychotics.1
b-Lactams are a family of antibiotics frequently prescribed in
the setting of severe infection in intensive care units (ICUs). The
indication may be for either empirical or directed therapy. In the
setting of the dynamic physiological changes that patients may
undergo secondary to disease processes and clinical interven-
tions, significantly altered b-lactam PK is common.2 – 7 Spe-
cifically, increases in volume of distribution (V) and dramatic
fluctuations in drug clearance are common in critically ill patients,
leading to sub-therapeutic or toxic concentrations in a large pro-
portion of ICU patients when standard dosing strategies are
used.8,9 In view of the difficult-to-predict PK and the importance
of early and appropriate antibiotic therapy in reducing mortality
rates,10 – 14 TDM of b-lactam antibiotics is increasingly being
reported in critically ill patients.9,15,16 The aim of b-lactam TDM
is to provide doses of antibiotic that maintain unbound b-lactam
concentrations above bacterial MICs over a desired percentage of
the dosing period (% fT.MIC).
17–19
The feasibility of performing b-lactam TDM as a part of routine
care in ICUs has been reported by various ICUs.9,15,16 Despite
emerging evidence of the value of b-lactam TDM as a dose opti-
mization strategy in ICUs, there is limited information on how it is
actually performed in the clinic.9,19–22 The aim of this paper is to
describe in detail the various approaches used for b-lactam TDM
in ICUs.
Methods
A questionnaire survey was developed to describe various aspects relating
to the conduct of b-lactam TDM in an ICU setting. The protocol items asso-
ciatedwith practical implementation of b-lactam TDM are listed in Table 1.
Contributing ICUs (or TDM units that perform TDM hospital-wide, including
ICUs) were identified by a literature review of publications on b-lactam
TDM and from ICUs known by the investigators to be using TDM for
b-lactams in ICU patients. Approval to conduct this low- and negligible-
risk study was obtained from the Human Research Ethics Committee at
the Royal Brisbane and Women’s Hospital, Australia (reference HREC/13/
QRBW/243).
Statistical analysis
Data were subject to descriptive statistical analysis and are presented as
the proportion of ICUs (%), mean (SD) or median (IQR) as appropriate.
Results
Response rate and ICU demographics
Nine of the 11 ICUs that were approached responded to the
survey. The survey was completed by ICU physicians (n¼3),
infectious disease physicians (n¼1), clinical pharmacologists
(n¼1) and clinical pharmacists (n¼4). The characteristics and
locations of the participating ICUs included are listed in Table 2.
The majority of the ICUs were located in European coun-
tries (66.7%).
Logistics of TDM programmes
The TDM programmes were primarily managed by ICU physicians
(n¼6), pharmacists (n¼5), infectious disease physicians (n¼3)
and clinical pharmacologists (n¼1), in conjunction with micro-
biologists and clinical biochemists depending on the nature of
the clinical cases. The median number of days per week when
TDM was available was 5 (IQR 4–5). The median number of
patients subject to TDM per day and per week ranged from 1 to
4 and from 1 to 15, respectively.
b-Lactams subject to TDM
The 21 b-lactam antibiotics subject to TDM across the various
ICUs are shown in Figure 1. The number of b-lactams monitored
by a single centre ranged between 3 and 12 (mean 7). All ICUs
Table 1. b-Lactam TDM practice information collected in the survey
b-Lactam TDM practice item surveyed Rationale
Number of ICU beds and ICU type Demographic characteristics of ICUs that perform b-lactam TDM
Median number of TDMs per day and per week
Personnel who manage TDM programme
Names of b-lactams subject to TDM
Inclusion and exclusion criteria Criteria each ICU uses to select patients that will be subject to TDM
Blood sample timing Timing of blood samples during a dosing interval for measurement of b-lactam concentrations
Sampling of body fluids other than blood Whether fluids other than blood are sampled for TDM
b-Lactam assay method Determine whether published methods are used to measure b-lactam concentrations and
whether total or free concentrations are measured
Measurement of bacterial pathogen susceptibility How and under which circumstances MICs are determined (e.g. published susceptibility
breakpoints, Vitek 2 and/or Etest)
Time delay between sampling and availability of
results to treating clinician
PK/PD targets for dose adjustment (i) What therapeutic target is used? i.e. which % fT.MIC is used?
(ii) What is the PK/PD threshold of toxicity?
Dose adjustment methods What strategies are used to adjust doses when concentrations are deemed too low or too high?
% fT.MIC, percentage of the dosing period during which the free concentration of drug remains above the MIC for the pathogen.
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included piperacillin (administered co-formulated with tazobac-
tam) and meropenem for TDM. As shown in Figure 1, various
cephalosporins were also frequently subject to TDM.
Inclusion and exclusion criteria
There was significant heterogeneity across the protocols for
choosing which patients would be subject to b-lactam TDM. The
majority of the ICUs (n¼5) specifically targeted TDM to patients
with severe sepsis or septic shock. Other inclusion criteria were:
specific types of serious bacterial infection requiring prolonged
antibiotic treatment (e.g. brain abscess, endocarditis, meningitis);
impaired organ function [e.g. renal impairment, assumed aug-
mented renal clearance (ARC);5,23 liver failure/cirrhosis]; and
patients undergoing renal replacement therapy (RRT) and/or
extracorporealmembrane oxygenation (ECMO). Other patient fac-
tors included immunosuppression, organ transplantation, severe
burn injury and patient weight (underweight or obese). Some ICUs
performed TDM in the presence of multidrug-resistant pathogens,
suspected b-lactam toxicity and/or when b-lactams were admi-
nistered by continuous infusion.
Three facilities also performed b-lactam TDM in non-ICU
patients who met one or more of the above criteria. Exclusion cri-
teria included: (i) paediatric patients (age ,18 years) (n¼7); (ii)
patients whose b-lactam antibiotic treatment was expected to
be ceased within 24 (n¼2) or 72 h (n¼1) of sampling; (iii) prophy-
lactic antibiotic use (n¼1); and (iv) concomitant antimicrobials
with activity against the indicator organism of the microbiological
assay (Staphylococcus epidermidis, Clostridium perfringens or
Klebsiella pneumoniae depending on the assay) (n¼1).
PK sampling timing
All protocols sampled trough concentrations of b-lactams at
assumed PK steady state when administered by intermittent dos-
ing (steady statewasmostly defined as having been reached after
four doses or 24–48 h after onset of treatment). Sampling was
performed at PK steady state when the antibiotic was given by
a continuous infusion (frequently defined as four to five half-lives
after commencement of therapy or after a dose change). One ICU
obtained an additional sample at 30% of the dosing interval.
Multiple samples [immediately after dosing, then 30% (or 40%),
50% and 70% of the dosing interval] were taken in two units for
research purposes but not for dose adjustment calculations. Six
ICUs also performed TDM in body fluids other than blood.
Samples that could be subject to TDM included CSF (n¼5), peri-
toneal fluid (n¼4), RRT dialysate, urine and, rarely, pleural effu-
sion, bronchoalveolar lavage fluid, bile and joint aspirate.
b-Lactam assay methods
Microbiological assays were used in two units and chromato-
graphic methods elsewhere. Among the facilities that used chro-
matography, two units measured total and/or unbound b-lactam
concentrations for TDM, while other ICUs measured total concen-
trations only. The majority of the assay protocols were published
(n¼9; Table 3). Those that were not published were in-house pro-
tocols that had been validated by Valistat 2.0 (Arvecon, Germany)
or according to local regulatory guidelines.24,25HPLCwith ultravio-
let detection (HPLC/UV) was the predominant analytical system
used (n¼4); other systems used were ultra-performance liquid
chromatography–tandem mass spectrometry (UPLC–MS/MS)
and liquid chromatography–tandem mass spectrometry (LC–
MS/MS). Generally, antibiotic concentration results were available
to treating clinicians within 6–12 h from sampling time (when
samples were received by the laboratories within scheduled
hours) and up to 24–48 h in some facilities.
Determination of bacterial susceptibility
Two ICUsmeasured bacterial MICs routinely for TDM by themicro-
dilution broth method and the Phoenix Automated Microbiology
System (BD Diagnostic Systems, Sparks, MD), respectively. For
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Figure 1. Frequencywithwhichb-lactamantibioticswere included as part
of a TDM programme in surveyed ICUs.
Table 2. Details of the participating ICUs
n or
median (IQR)
Country
Australia 2
Belgium 2
France 1
Germany 1
Italy 1
Switzerland 1
USA 1
ICU bed numbers 30 (15–35)
ICU type
medical–surgical only 6
medical–surgical, with burns unit and/or other
subspecialty units
3
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others, MICs were measured by the disc method, Etest (bio-
Me´rieux, France) or the micro-dilution broth method only when
the pathogen was determined to be intermediately susceptible
to the antibiotic or where resistance to the prescribed antibiotic
was demonstrated with the Vitek 2 system (bioMe´rieux, France).
Surveyed ICUs adopted EUCAST (n¼8) or CLSI (n¼1) breakpoints
to determine PK/pharmacodynamic (PD) targets when MICs were
not measured. Two of the ICUs also reported using local hospital
antibiogram data to describe likely pathogen susceptibility.
PK/PD targets for dose adjustment
A minimum of 100% fT.MIC was adopted as the PK/PD target for
dose increase by six of the ICUs. Dose reduction was undertaken
mostly on a case-by-case basis by all units when toxicity (espe-
cially neurological) was suspected or concentrations were above
locally defined threshold concentrations for potential toxicity. Six
other targets for dose increase were described, as shown in
Table 4. Only four units would reduce the dose if concentrations
were above the recommended PK/PD targets for efficacy.
Method of dose adjustment
All ICUs adjusted the dose as soon as results became available.
Only two ICUs determined a new dosage by calculation of the
individual patient’s drug clearance frommeasured b-lactam con-
centrations. Other ICUs adopted more generalized dose adjust-
ment methods, as summarized in Table 5. All except one of the
Table 3. Published b-lactam assay methods used by the surveyed facilities
Analytical
system Antibiotics
Calibration curve range,
precision and accuracy
Interval between sampling
and availability of resultsa Reference
Microbiological
assay
amoxicillin/clavulanic acid, cefazolin, cefepime,
cefotaxime, ceftazidime, ceftriaxone, doripenem,
ertapenem, imipenem, meropenem, piperacillin/
tazobactam, ticarcillin
calibration curve ranges
chosen depending on
antibiotics and test
organism
24–48 h Kitzis26
precision:+10%–15%
HPLC/UV aztreonam, cefepime, ceftazidime, cefuroxime,
meropenem, piperacillin
2–200 mg/L 12 h (or 3 days
over weekend)
Wolff et al.27
precision: CV,11%
accuracy:+30%
ampicillin, benzylpenicillin, cefalotin, cefazolin,
ceftazidime, ceftriaxone, dicloxacillin,
ertapenem, flucloxacillin, meropenem,
piperacillin, ticarcillin
1–500 mg/L (except
meropenem 1–250 mg/L)
within 12 h McWhinney
et al.28
precision: CV,10%
accuracy:+6%
ampicillin, benzylpenicillin, cefalotin, cefazolin,
ceftriaxone, dicloxacillin, ertapenem,
flucloxacillin, meropenem, piperacillin
unbound antibiotics:b 0.1–
50 mg/L (except piperacillin
0.1–100 mg/L)
within 12 h Briscoe
et al.29
precision: CV,9.4%
accuracy:+15%
meropenem 3–50 mg/L 6 h Bias et al.30
ceftazidime 1–200 mg/L within 6 h Hanes et al.31
precision: CV,6.2%
accuracy: 97.5%–105.5%
HPLC meropenem 10–70 mg/L within 6 h Mendez
et al.32LOQ: 12.85 mg/L
precision: CV,0.85%
accuracy: 99.1%–100.1%
UPLC–MS/MS amoxicillin, ampicillin, cefazolin, cefuroxime,
ceftazidime, clavulanic acid, meropenem,
piperacillin, tazobactam
0.5–100 mg/L (except
piperacillin 1.5–100 mg/L)
6 h Carlier et al.33
precision: 10%–20% at LOQ
and 3%–15% at higher
levels
accuracy: 86.8%–101.5%
LC–MS/MS ampicillin, cefazolin, cefepime, cefmetazole,
cefotaxime, doripenem, meropenem, piperacillin
0.1–50 mg/L (except
doripenem 0.5–50 mg/L)
within 6 h Ohmori
et al.34
precision: CV,14.6%
accuracy: 86.4%–112.3%
CV, coefficient of variation.
aLimited to samples received by the laboratories before scheduled cut-off times on days that TDM was available.
bConcentrations of unbound (free) b-lactam antibiotics were measured directly.
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ICUs increased the dose based on b-lactam concentrations, sus-
ceptibility of the clinical isolate and the nature of infection, with-
out a definite maximum dose per day for any specified antibiotic.
Eight units performed follow-up TDM. This was done regularly
after dose adaptation (generally every 24–48 h), after dose
changes or if changes in a patient’s characteristics were antici-
pated to alter b-lactam PK.
Discussion
This is the first multicentre survey to describe the clinical practice
of b-lactam TDM in an international selection of ICUs that cur-
rently use TDM for clinical purposes. This report demonstrates
the variation in b-lactam TDM practice, especially in selection of
b-lactams and the patient population for TDM, drug assay meth-
ods, PK/PD targets and dose adjustment strategies. Despite quite
significant variations in practice, the general steps that pertain to
b-lactam TDM can be summarized as illustrated in Figure 2.
The list of b-lactam antibiotics for TDM in each ICU varied, likely
due to differences in the availability of b-lactams in different
countries, the hospital formulary, prescribing habits, the case
mix of patients and the pattern of bacterial susceptibility.35–41
Piperacillin, meropenem, ceftazidime, ceftriaxone and cefazolin
were subject to TDM in the majority of the ICUs surveyed. This
finding is consistent with their high prevalence of usage36,38,42
and the variable PK that has previously been published in critically
ill patients.21,43–50Despite an increasing amount of PK data in crit-
ically ill patients, the variability in the inclusion criteria for TDM
may reflect the lack of robust dosing data.
A range of validated chromatographic b-lactam assays were
most commonly used for TDM. All assays were reported to meet
regulatory limits of accuracy and precision, with calibration curve
concentration ranges that are clinically appropriate. However,
some assays have a relatively high limit of quantification (LOQ)
(3 and 10 mg/L for meropenem). Although a high LOQ will not
cause under-dosing in practice, it may result in unnecessarily
high antibiotic exposures in some patients infected by highly sus-
ceptible bacteria. Of note, only two ICUs directly measured the
unbound concentrations of b-lactams. Given that the unbound
concentration of b-lactams is responsible for bacterial killing
and that hypoalbuminaemia occurs in 40% of critically ill
patients,51,52 measuring total concentrations only may lead to
under- or over-estimation of the unbound concentrations and
may jeopardize the accuracy of the method, especially for highly
protein-bound antibiotics.53 Most assays are efficient and provide a
same-day turn-around for results; however, the availability of TDM
was still limited to certain hours and days of theweek in some facil-
ities. The chromatography technique used is associated with high
equipment and personnel costs, which might theoretically affect
the cost–effectiveness of b-lactam TDM. Microbiological assays
performed by some units are an alternative to chromatography
with comparable precision and robustness that could overcome
the disadvantages of chromatography in terms of costs.26
However, its processing time is comparatively much longer.
Interference of concomitant antibiotics with indicator bacteria
also limits the use of bioassay in clinical practice.
Only two of the ICUs surveyed routinely measured bacterial
MICs for b-lactam TDM. Although other units reported measuring
MICs by Etest or Vitek 2 where deemed necessary, the majority of
ICUs used local antibiograms or EUCAST breakpoints to determine
MICs for PK/PD targets for most patients. Whilst useful for most
clinical situations, the reporting of EUCAST breakpoints by micro-
biology laboratories is mostly categorical (susceptible, intermedi-
ate or resistant), only providing the upper MIC threshold for each
category, leading to a high target dose that is unnecessary for
more susceptible pathogens. In addition, factors used for deter-
mination of breakpoints are dynamic, and the predictive value
of breakpoints might not hold when the bacterial epidemiology
changes or a new resistance mechanism emerges.
Although themajority of ICUs adopted 100% fT.MIC as a PK/PD
threshold for dose increase, targets for b-lactam TDM remain
Table 4. List of PK/PD targets for dose adjustment adopted by selected ICUs
PK/PD targets Specific conditions
For dose increase 100% fT.MIC (n¼5)
100% fT2–4×MIC (n¼1)
50% fT.4×MIC (n¼1) intermittent bolus dosing
100% fT.4×MIC (n¼2) continuous infusion
40% fT.4×MIC (n¼1) for meropenem
50% fT.4×MIC (n¼1) for piperacillin, aztreonam and cefuroxime
70% fT.4×MIC (n¼1) for cefepime and ceftazidime
Threshold of potential
toxicity for dose reduction
100% fT10×MIC (n¼4)
100% fT8×MIC (n¼1) MIC for Pseudomonas aeruginosa of the antibiotic
100% fT6×MIC (n¼1) continuous infusion
100% fT4–5×MIC (n¼1) in the presence of susceptible pathogens
steady-state concentration exceeding 2×maximum
exposure expected in general population; e.g.
piperacillin .100 mg/L (.32 g/24 h in normal
patients), meropenem .32 mg/L (.12 g/24 h in
normal patients) (n¼1)
continuous infusion
% fT.x×MIC, percentage of the dosing period during which the free (unbound) concentration was x times the MIC for targeted pathogen.
Wong et al.
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diverse. In vitro and animal studies demonstrated that the PK/PD
targets of fT.MIC of 35%–40%, 30% and 20% are bacteriostatic
for cephalosporins, penicillins and carbapenems, respectively,
whilst 40% fT.MIC for carbapenems, 50% for penicillins and
monobactams, and 60%–70% for cephalosporins are required
for maximum bactericidal effect.54–57 However, more aggressive
PK/PD targets have also been suggested. In a study of critically ill
patients with bacteraemia and sepsis treated with cefepime and
ceftazidime, 100% fT.MIC was associated with significantly
greater clinical cure and bacteriological eradication compared
with fT.MIC ,100%.
18 Similar data were found by Tam et al.,58
except for a higher PK/PD target with cefepime. The most signifi-
cant predictor of successful clinical andmicrobiological responses
was determined to be the fCmin/MIC ratio of 5 in a study of mero-
penem PD in patients with lower respiratory tract infections.59 A
similar targetwas suggested in an in vitro PKmodel of ceftazidime
against Pseudomonas aeruginosa by Mouton and den Hollander
comparing the effectiveness of intermittent and continuous
b-lactam infusion.60 In view of the varied information available
in the literature, the variation in clinical practice we observed is
not unexpected, although PK/PD targets selected by individual
ICUs all cited published literature, albeit different literature.
Similar uncertainty in defining a potential toxicity threshold was
observed, which is consistent with the scarcity of published data
on this topic.61–63 These observations also support the need for
further studies that robustly define PK/PD targets for
b-lactam TDM.
Apart from two ICUs that calculated individual PK parameters
for each new dosing regimen, the strategies for dose adjustment
reported were quite non-specific. Other approaches to dose adjust-
ment were not necessarily widely used or available. The availability
of nomograms for b-lactam dosing is limited.64 PK software could
also be applied to more accurately define therapeutic doses,
although such software has not been widely tested or validated.65
In addition to rapid achievement of therapeutic concentrations,
accuracy and appropriateness of dose adjustment are needed to
maximize the advantages that b-lactam TDM could provide, as is
the case when TDM is applied to any antibiotic.66–68
Limitation of the study
The differences in clinical environment and antibiotic usage strat-
egy between institutions and the small sample of ICU populations
limit the generalizability of our findings. Data collection by con-
venience sampling may also have introduced a selection bias,
although the response rate was high and we are unaware of
other centres also performing b-lactam TDM at the time of the
survey. Nevertheless, such a bias is probably unavoidable with a
limited number of centres around theworld known to be perform-
ing TDM routinely, and this study is the largest representation of
ICUs adopting this strategy in b-lactam antibiotic dosing.
Conclusions
This is the first paper describing the practice strategies used by
ICUs that perform b-lactam antibiotic TDM as part of routine clin-
ical care.We found large variations in the b-lactams tested aswell
as the patients selected for TDM, drug assay methods and dose
adjustment strategies. In particular, this survey highlights the
controversies that apparently exist relating to the question of
which PK/PD targets should be used in critically ill patients. We
await robustly designed randomized controlled trials to address
this gap in the literature.
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Patient factors: Pathogen factors:
- disease process - bacterial strain
- site of infection
- antibiotic
susceptibilities (MICs)
Selection of antibiotic and
PK/PD target (fT>MIC)
Selection of individual dosing
regimen
Blood sampling and
quantification of antibiotic
concentration
Calculation of PK/PD
- organ function
- type of ICU
interventions received
- comorbidities
Figure 2. General process used among participating sites for application
of b-lactam TDM.
Table 5. Methods for dose adjustment based on initial mode of drug
administration
Dose adjustment strategy
Dose increase increase dose administration frequency by 25%–50%
25%–50% increased dose with same frequency
change to extended infusion (if concentration within 20%
of target)
change to continuous infusion (if at maximum daily dose
according to product information)
Dose
reduction
decrease frequency of administration at the same dose
25%–50% decrease in dose with same dosing frequency
withhold therapy for 1 day
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